介入放射学杂志2024,Vol.33Issue(2) :186-190.DOI:10.3969/j.issn.1008-794X.2024.02.016

经动脉灌注化疗联合碘化油化疗栓塞治疗晚期结直肠癌

Transarterial infusion chemotherapy combined with lipiodol chemoembolization for the treatment of advanced colorectal cancer

丁小龙 王帅 马耀臻 殷美攀 刘涛 靳水玲 李晓冰 李春霞 韩新巍 吴刚
介入放射学杂志2024,Vol.33Issue(2) :186-190.DOI:10.3969/j.issn.1008-794X.2024.02.016

经动脉灌注化疗联合碘化油化疗栓塞治疗晚期结直肠癌

Transarterial infusion chemotherapy combined with lipiodol chemoembolization for the treatment of advanced colorectal cancer

丁小龙 1王帅 1马耀臻 1殷美攀 1刘涛 2靳水玲 3李晓冰 1李春霞 1韩新巍 1吴刚1
扫码查看

作者信息

  • 1. 450052 河南郑州 郑州大学第一附属医院介入科
  • 2. 450052 河南郑州 郑州大学第一附属医院胃肠外科
  • 3. 450052 河南郑州 郑州大学第一附属医院肿瘤科
  • 折叠

摘要

目的 探讨经导管动脉灌注化疗(TAI)联合碘化油化疗栓塞治疗晚期结直肠癌(CRC)的安全性、可行性及有效性.方法 回顾性分析 2016 年 6 月至 2022 年 12 月郑州大学第一附属医院收治的 37 例接受TAI联合碘化油化疗栓塞治疗的晚期CRC患者临床资料.评价其疗效,记录无疾病进展生存期(PFS),观察有无严重并发症发生.结果 37 例患者共成功接受 55 次TAI和碘化油化疗栓塞治疗,均获得成功.碘化油乳剂使用剂量为 2.9 mL(0.8~10 mL).无出血、肠穿孔等严重并发症发生.中位随访时间为 24 个月(3~48 个月),术后 1、3、6、12 个月客观缓解率(ORR)分别为 67.6%(25/37)、67.6%(25/37)、64.9%(24/37)、56.8%(21/37),疾病控制率(DCR)分别为 91.9%(34/37)、91.9%(34/37)、89.2%(33/37)、81.1%(30/37).中位PFS为 16 个月(2~47 个月).截至末次随访,22 例患者生存,15 例患者死于肿瘤终末期.结论 初步证明TAI联合碘化油化疗栓塞治疗晚期CRC安全有效,为晚期CRC患者提供了一种新治疗手段.

Abstract

Objective To discuss the clinical safety,feasibility and efficacy of transcatheter arterial infusion chemotherapy(TAI)combined with lipiodol chemoembolization in the treatment of advanced colorectal cancer(CRC).Methods The clinical data of 37 patients with advanced CRC,who received TAI combined with lipiodol chemoembolization at the First Affiliated Hospital of Zhengzhou University of China between June 2016 and December 2022,were retrospectively analyzed.The clinical efficacy was evaluated,the progression-free survival(PFS)and the serious complications were recorded.Results A total of 55 times of TAI combined with lipiodol chemoembolization procedures were successfully accomplished in the 37 patients.The mean used amount of lipiodol emulsion was 2.9 mL(0.8-10 mL).No serious complications such as bleeding and intestinal perforation occurred.The median follow-up time was 24 months(range of 3-48 months).The postoperative one-month,3-month,6-month and 12-month objective remission rates(ORR)were 67.6%(25/37),67.6%(25/37),64.9%(24/37)and 56.8%(21/37)respectively,and the postoperative one-month,3-month,6-month and 12-month disease control rates(DCR)were 91.9%(34/37),91.9%(34/37),89.2%(33/37)and 81.1%(30/37)respectively.The median PFS was 16 months(range of 2-47 months).As of the last follow-up,22 patients survived and 15 patients died of terminal stage of tumor.Conclusion Preliminary results of this study indicate that TAI combined with lipiodol chemoembolization is clinically safe and effective for advanced CRC,and it provide a new therapeutic method for patients with advanced CRC.

关键词

灌注化疗/化疗栓塞/碘化油/结直肠癌/介入放射学

Key words

infusion chemotherapy/chemoembolization/lipiodol/colorectal cancer/interventional radiology

引用本文复制引用

基金项目

河南省中青年卫生健康科技创新领军人才培养项目(YXKC2020018)

出版年

2024
介入放射学杂志
上海市医学会

介入放射学杂志

CSTPCD北大核心
影响因子:1.866
ISSN:1008-794X
参考文献量20
段落导航相关论文